Hecht Beth 4
4 · Xeris Biopharma Holdings, Inc. · Filed Feb 2, 2026
Research Summary
AI-generated summary of this filing
Xeris (XERS) CLO Beth Hecht Sells 16,667 Shares
What Happened
Beth Hecht, Chief Legal Officer and Corporate Secretary of Xeris Biopharma (XERS), received equity awards and completed both withholding and an open-market sale. On Jan 30, 2026 she was granted 121,293 restricted stock units (RSUs) and 162,162 stock options (both $0 acquisition price) that vest in equal annual installments over three years. Following RSU vesting, 169,555 shares were withheld to cover tax obligations on Jan 31, 2026 (net value withheld ≈ $1,247,925 at a weighted $7.36). Separately, on Feb 2, 2026 she sold 16,667 shares in the open market for $124,147 (weighted avg reported $7.45; sales ranged $7.25–$7.59).
Key Details
- Transaction dates: Grants on Jan 30, 2026; tax-withholding/net settlement on Jan 31, 2026; open-market sale on Feb 2, 2026.
- Grants: 121,293 RSUs and 162,162 stock options (both vest over three years subject to continued service).
- Withholding for taxes: 98,375 + 46,914 + 24,266 = 169,555 shares withheld at $7.36 (total ≈ $1,247,925) to satisfy tax/remittance obligations for vested RSUs. (Filed as "Payment of exercise price or tax liability" transactions.)
- Open-market sale: 16,667 shares sold under a Rule 10b5-1 plan for proceeds of $124,147 (weighted avg $7.45; prices ranged $7.25–$7.59).
- Footnotes: RSUs/options granted under the Company’s 2018 Plan; net settlement tax withholding and 10b5-1 plan apply.
- Shares owned after transactions: Not specified in the filing.
- Filing timeliness: Form 4 filed Feb 2, 2026 — within the SEC’s two-business-day reporting window for the reported dates.
Context
- This filing shows equity compensation (RSU and option grants) and routine tax withholding (net settlement) rather than a large discretionary sale. The only open-market sale (16,667 shares) was done under a pre-established 10b5-1 plan. For retail investors, purchases or grants can signal long-term alignment; withholding and immediate sales to cover taxes are common administrative steps and do not necessarily indicate a change in insider sentiment.
Insider Transaction Report
- Award
Common Stock
[F1]2026-01-30+121,293→ 1,429,396 total - Tax Payment
Common Stock
[F2]2026-01-31$7.36/sh−98,375$724,040→ 1,331,021 total - Tax Payment
Common Stock
[F2]2026-01-31$7.36/sh−46,914$345,287→ 1,284,107 total - Tax Payment
Common Stock
[F2]2026-01-31$7.36/sh−24,266$178,598→ 1,259,841 total - Sale
Common Stock
[F3][F4]2026-02-02$7.45/sh−16,667$124,147→ 1,243,174 total - Award
Stock Option (Right to Buy)
[F5]2026-01-30+162,162→ 162,162 totalExercise: $7.36Exp: 2036-01-30→ Common Stock (162,162 underlying)
Footnotes (5)
- [F1]These shares were acquired pursuant to a restricted stock unit grant under the Company's 2018 Stock Option and Incentive Plan (the "Plan"). Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. These shares shall vest in equal annual installments over three years, subject to continued employment through such vesting date.
- [F2]Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of restricted stock units vested as of January 31, 2026.
- [F3]The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- [F4]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.250 to $7.590, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F5]These stock options were acquired pursuant to a grant under the Plan. These stock options shall vest in equal annual installments over three years, subject to continued service through such vesting date.